In this article, we’re going to talk about the 12 NASDAQ stocks with biggest upside potential according to analysts.
Potomac Wealth Advisors president Mark Avallone joined CNBC’s ‘The Exchange’ on November 16 to discuss where he sees investing opportunities following Trump’s election. He believes investing in the tech sector makes the most sense given the implications of the 2024 election results for the financial markets. He noted that the election has shifted the underlying dynamics affecting businesses, particularly regarding regulation and taxation. The new administration has changed the previous climate of heightened regulation and discussions around increasing capital gains and corporate taxes. Avallone believes that the potential for reduced regulation and lower taxes on corporations could create a more favorable environment for business growth.
He emphasized that corporate America’s ability to deliver earnings will be crucial, relying on continued efficiencies and advancements in technology. This perspective supports his thesis that investing in technology remains a sound strategy for investors. When discussing specific stocks, Avallone highlighted major tech companies from the MAG7 as particularly attractive. He expressed confidence that the current administration would foster a more supportive environment for these companies, allowing them to thrive.
Avallone also touched on the defense sector, which has historically benefited from global conflicts. He pointed out that defense companies have shown resilience and believes that ongoing global tensions will sustain demand for defense stocks, providing a hedge against market volatility.
However, Avallone expressed caution regarding the healthcare sector, which has been lagging due to heavy regulation and political scrutiny. He noted that despite an aging population driving demand for medical equipment, regulatory pressures have hindered growth in this area. Overall, his analysis underscores a cautious optimism about investing in technology and defense while highlighting potential challenges within healthcare as businesses navigate the post-election landscape.
Methodology
We sifted through Finviz to compile a list of 30 NASDAQ stocks with high upside potentials. We then selected the 12 stocks with the biggest upside potential according to analysts. The stocks are ranked in ascending order of their analysts’ upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
12. Dyne Therapeutics Inc. (NASDAQ:DYN)
Average Upside Potential as of November 21: 73.44%
Dyne Therapeutics Inc. (NASDAQ:DYN) is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people with genetically driven diseases. Its primary focus is on myotonic dystrophy type 1 (DM1), and Duchenne muscular dystrophy (DMD), among other rare diseases.
A significant milestone for the company was the FDA’s clearance of the IND application for DYNE-101, a drug designed to treat DM1. The drug is being evaluated in the ongoing Phase 1/2 ACHIEVE trial for adults with DM1. New data from this trial, including safety, efficacy, and patient-reported outcomes, is expected in early January 2025. This data will inform the go-forward dose and regimen for DYNE-101.
In parallel, the company is also advancing its DYNE-251 program for Duchenne muscular dystrophy (DMD). Positive results from the Phase 1/2 DELIVER trial have led to the start of a new study to test a specific dosage of DYNE-251 (20 mg/kg every 4 weeks). The company is aiming for faster approval processes for both DYNE-101 and DYNE-251.
Despite challenges, with positive clinical data and regulatory approvals, the company is well-positioned to bring innovative therapies to patients with significant unmet needs.
11. SpringWorks Therapeutics Inc. (NASDAQ:SWTX)
Average Upside Potential as of November 21: 76.03%
SpringWorks Therapeutics Inc. (NASDAQ:SWTX) is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for populations suffering from rare diseases and cancer. Its lead product, OGSIVEO (nirogacestat), is an FDA-approved oral treatment for adult patients with progressing desmoid tumors.
It has made significant progress in the treatment of desmoid tumors. In September, over 800 unique patients filled prescriptions for OGSIVEO. As of the third quarter, ~420 treatment centers have ordered OGSIVEO since its approval and around 65% of patients are receiving the medication in convenient blister pack formats, which are convenient, easy to use, and help patients adhere to their medication schedule. The company aims to complete the full transition to blister packs by the end of the year.
The company reported strong third-quarter 2024 results, driven by a 23% quarter-over-quarter increase in net product revenue to $49.30 million coming from continued strong commercial execution of the OGSIVEO launch. SpringWorks Therapeutics Inc. (NASDAQ:SWTX) has achieved significant growth, which places it well within its industry to return promising shareholder value.
10. VinFast Auto Ltd. (NASDAQ:VFS)
Average Upside Potential as of November 21: 77.89%
VinFast Auto Ltd. (NASDAQ:VFS) is an EV manufacturer based in Vietnam and is a subsidiary of Vingroup, one of Vietnam’s largest private enterprises. It focuses on designing and producing electric cars, e-scooters, and e-buses, targeting domestic and international markets. It operates through 3 main segments: Automobiles, E-scooters, and Spare Parts & Aftermarket Services.
The company has made significant strides in its global expansion and sales. In H1 2024, it delivered 21,747 vehicles, a 92% increase year-over-year. In Q2 alone, it delivered over 12,000 vehicles, intending to deliver a total of ~80,000 EVs in the full year 2024. Revenue generated in the second quarter of 2024 totaled $358.56 million, which was lower than Street estimates. Still, the positive momentum continued into Q3, with 21,912 EVs delivered, marking a 66% increase from the previous quarter and a 116% increase year-over-year.
VinFast Auto Ltd. (NASDAQ:VFS) is very active in Southeast Asia, particularly Indonesia and Thailand. In Indonesia, it established partnerships with 5 dealerships and opened its first store in April 2024. By late summer, it had launched 15 additional dealer stores and introduced 2 new EV models. In Thailand, it signed a letter of intent with 15 initial dealers. It’s also expanding in the Middle East, focusing on Oman and Qatar, with plans to open its first showroom in Doha in Q3 2024. In the US, it aims to establish 125 sales points and currently operates 18 dealerships across 7 states.
With strong sales growth, aggressive expansion into key markets, and a focus on innovation, the company is well-positioned to capitalize on the growing demand for electric vehicles.
9. Sunrun Inc. (NASDAQ:RUN)
Average Upside Potential as of November 21: 83.40%
Sunrun Inc. (NASDAQ:RUN) provides photovoltaic systems and battery energy storage products, primarily for residential customers. It specializes in solar energy systems for homeowners, offering services that allow customers to adopt solar power with little to no upfront costs.
In the third quarter of 2024, the company recorded a 4.62% decline in its year-over-year revenue, generating an amount of $537.17 million, which was lower than analyst expectations. Yet, Q3 marked the installation of over 135,000 solar and storage systems, with storage attachment rates reaching 60% of installations during the quarter.
The company has activated New York’s largest residential virtual power plant, leveraging over 300 solar-plus-storage systems. This innovative program enhances grid reliability by synchronizing home batteries to discharge 20% of their stored solar energy during peak demand periods. Participants receive free or discounted batteries and bill credits, while also benefiting from backup power for their homes.
Sunrun Inc. (NASDAQ:RUN) is well-positioned for growth. Investments in infrastructure and technology are enhancing margins and positioning it for long-term success.
8. Geron Corp. (NASDAQ:GERN)
Average Upside Potential as of November 21: 85.87%
Geron Corp. (NASDAQ:GERN) is a biotechnology company specializing in developing and commercializing therapeutic products for cancer that inhibit telomerase, an enzyme linked to cell division and cancer proliferation. Its primary product, Imetelstat, is a first-in-class telomerase inhibitor to treat various blood cancers, including myelodysplastic syndromes and myelofibrosis.
The brand name for Imetelstat at the company is RYTELO. In the first full quarter of RYTELO’s launch in the US, which is Q3 2024, the company had $28.27 million in net product revenue, surpassing expectations by $9.26 million. This strong performance reflects both the significant unmet need in lower-risk MDS and RYTELO’s differentiated clinical profile, causing revenue to grow by 17,138.41% year-over-year.
RYTELO became available to prescribers on June 27 and the demand has steadily increased month-over-month, with 388 ordering centers representing ~45% of key targeted accounts. Its efficacy in improving red blood cell transfusion independence and hemoglobin levels is well-recognized by treating physicians. It’s also important to note that ~70% of US-covered lives have implemented medical coverage policies consistent with RYTELO’s FDA label.
Management anticipates potential EU approval for RYTELO in H1 2025, following a CHMP review expected to conclude in late 2024 or early 2025. It’s actively preparing for a potential launch in select EU markets starting in 2026. These efforts, combined with the company’s current financial performance position Geron Corp. (NASDAQ:GERN) to become an industry leader.
7. VEON Ltd. (NASDAQ:VEON)
Average Upside Potential as of November 21: 102.38%
VEON Ltd. (NASDAQ:VEON) is a multinational telecommunication and digital services company, providing a range of connectivity and internet services in several countries. It offers mobile and fixed-line telecommunications, as well as various digital services including financial technology and entertainment platforms. It’s committed to enhancing digital infrastructure in its markets and has recently focused on expanding its offerings through partnerships and innovative solutions.
The company is significantly focused on AI as part of its strategy to enhance customer experiences and drive business growth. Through its AI1440 framework, it aims to integrate AI into daily life, developing local language models to support under-resourced languages in its markets, such as Urdu in Pakistan. it employs augmented intelligence to personalize services and improve customer interactions, while also using AI for data analytics to support local businesses, like optimizing retail experiences in Uzbekistan.
VEON Ltd. (NASDAQ:VEON) recently launched Hambi, an AI-powered super app in Uzbekistan. This all-in-one platform offers services like e-health, car insurance, digital marketplaces, travel, entertainment, fintech, and gaming. Hambi aims to provide a seamless user experience and personalized recommendations through AI-powered features. This launch aligns with the company’s Digital Operator 1440 strategy, which focuses on delivering essential digital services to customers.
With a focus on AI-powered initiatives like Hambi, it is well-positioned to capitalize on the growing demand for digital services in its markets.
6. Legend Biotech Corp. (NASDAQ:LEGN)
Average Upside Potential as of November 21: 106.32%
Legend Biotech Corp. (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) oncology therapies, a type of immunotherapy that harnesses the body’s own immune system to fight cancer. The lead candidate that falls under this therapy is the company’s lead product candidate, LCAR-B38M, also more commonly known as CARVYKTI (ciltacabtagene autoleucel), which targets multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow and is in advanced clinical trials.
Its strong third-quarter 2024 results were driven by the impressive growth of CARVYKTI. Net trade sales of CARVYKTI reached approximately $286 million, representing an 87.6% year-over-year and 53.2% quarter-over-quarter increase. CARVYKTI demonstrated a 45% reduction in the risk of death compared to standard therapies in multiple myeloma patients. The company received approval for CARVYKTI production in Belgium, expanding its manufacturing capacity in Europe. It has also expanded outpatient treatment options, with outpatient administration now comprising up to 48% of CARVYKTI’s volume.
However, Legend Biotech Corp. (NASDAQ:LEGN) reported a net loss of $0.68 per share for the quarter, primarily due to unrealized foreign exchange losses and increased selling and distribution expenses. The overall Q3 2024 revenue was still up 66.86% year-over-year. With the impressive growth of CARVYKTI, the company is well-positioned to capitalize on the growing demand for this innovative therapy.
TimesSquare Capital Management U.S. Focus Growth Strategy stated the following regarding Legend Biotech Corporation (NASDAQ:LEGN) in its Q2 2024 investor letter:
“Pulling back by -27% was Legend Biotech Corporation (NASDAQ:LEGN), a biotechnology developer of cell therapies to treat blood cancers such as multiple myeloma and leukemia. Recently both the European Union and the FDA approved the use of Legend’s Carvykti treatment of multiple myeloma. Some investors may have been concerned about possible supply delays as Legend ramps up production. Though with a long-standing agreement with Johnson & Johnson and a new partnership with Novartis for increasing production capacity, we see a long runway of growth ahead. Later in the quarter, there were concerns surrounding potential negative impacts from Congress’s draft BIOSECURE Act, which would bar certain Chinese-controlled biotechnology companies from U.S. government contracts. Our initial view is that Legend may not fall under the scope of the Act, though in our discussions with Legend’s management they seem ready to take steps to avoid possible negative outcomes from the Act. However, with that potential risk we removed the position from our concentrated strategy.”
5. Ideaya Biosciences Inc. (NASDAQ:IDYA)
Average Upside Potential as of November 21: 118.80%
Ideaya Biosciences Inc. (NASDAQ:IDYA) is a clinical-stage synthetic lethality-focused precision medicine oncology company committed to discovering and developing targeted therapeutics for patient populations selected using DNA sequencing and other molecular diagnostics. Its lead product includes IDE397, aimed at solid tumors with certain genetic characteristics.
The company recently announced positive interim Phase 1 expansion data for IDE397, a potential first-in-class MAT2A inhibitor, in MTAP-deletion urothelial cancer (UC) and non-small cell lung cancer (NSCLC) patients. The data, presented at the EORTC-NCI-AACR Symposium (ENA 2024), demonstrated a 33% overall response rate by RECIST 1.1, including one complete response and eight partial responses. The drug was well-tolerated, with no drug-related serious adverse events.
It is advancing IDE397 as a monotherapy and in combination with other therapies, including Trodelvy, in MTAP-deletion solid tumors. The company believes that IDE397 has the potential to address the significant unmet needs of these patient populations.
The recent positive clinical data for IDE397 highlights the company’s potential to address significant unmet medical needs in oncology. While Ideaya Biosciences Inc. (NASDAQ:IDYA) is still in its early stages and faces financial challenges, its innovative approach and strong pipeline position it for long-term growth and value creation for shareholders.
4. Icahn Enterprises (NASDAQ:IEP)
Average Upside Potential as of November 21: 125.49%
Icahn Enterprises (NASDAQ:IEP) is a diversified holding company that operates across multiple sectors, including investment, energy, automotive, food packaging, real estate, home fashion, pharmaceuticals, railcar, mining, and metals. Its investment segment manages proprietary capital through various private investment funds. The energy division refines and markets fuels and manufactures fertilizers. It also engages in automotive repair services and real estate leasing and development.
The company’s value decreased in the third quarter of 2024, dropping by $423 million. Revenue in Q3 was lower than Street expectations and dropped 25.69% as compared to the year-ago period, recording an amount of $2.22 billion. While some investments, like the investment funds, performed well, up 8% year-over-year, others, such as CVR Energy and the auto service business, struggled.
Icahn Enterprises (NASDAQ:IEP) is actively taking steps to improve its auto service business, including making management changes. In Q3, the Auto segment saw a $70 million decrease in net sales and other revenues year-over-year. Automotive services revenues declined by $51 million due to operational issues such as insufficient inventory, staffing levels, and reduced consumer spending on automotive repairs and maintenance. The aftermarket parts business contributed to a $20 million decrease in revenue.
The recent management changes in the auto segment are already yielding positive results, with a significant reversal in revenue trends. Icahn Enterprises (NASDAQ:IEP) believes in its long-term strategy and expects to generate strong returns for shareholders in the future.
Here is what CrossingBridge Advisors has to say about Icahn Enterprises L.P. (NASDAQ:IEP) in its Q3 2022 investor letter:
“Icahn Enterprises LP, headed by investor Carl Icahn, is a diversified holding company with interests in investments, energy, automotive, food packaging, real estate, home fashion and pharmaceuticals. The investment segment derives revenues from gains and losses from investment transactions. Other operating segments, in most cases, are independently operated businesses obtained through a controlling interest.
As of 2Q22, Icahn Enterprises had Indicative Net Asset Value of $6.6 billion, consolidated debt of $7.1 billion and total liquidity, comprised of cash, investment funds and revolving credit availability, of $7.2 billion. Moreover, as of the end of 3Q22, it had an equity market capitalization of $16.0 billion. Thus, we have no concern regarding credit quality. We have traded in and out of the IEP 4.75% senior unsecured bond, due September 2024, since it was issued in February 2020.
In 3Q22, amidst the downdraft in the high yield market, we were able to purchase these bonds at a yield to maturity over 8.20%, very attractive for a 2-year note with such strong credit quality. Purchased at a discount, the bond would have an even higher annualized total return were the company to redeem it prior to September 15, 2023, when it becomes a current obligation. We expect to continue adding to this position opportunistically.”
3. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Average Upside Potential as of November 21: 145.40%
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is a biopharmaceutical company that specializes in developing innovative therapies using its proprietary RNA interference (RNAi) technology to target and silence specific genes responsible for various diseases. The lead product candidate, ARO-AAT, is designed to treat alpha-1 antitrypsin deficiency, a genetic disorder that can lead to liver disease and lung problems.
It’s working on a pipeline of 20+ drugs, with the first, plozasiran, expected to launch in 2025 in familial chylomicronemia syndrome (FCS) and revolutionize the treatment of several lipid disorders. A key advantage of plozasiran is its unique mechanism of action, which allows it to significantly lower triglyceride levels, positioning it as a potential best-in-class treatment.
A recent significant milestone for the company was the successful completion of the Phase 3 PALISADE study for plozasiran. The study met its primary endpoint and key secondary endpoints, demonstrating the drug’s efficacy and safety. This achievement validates its scientific approach and positions the company for future growth and success.
Baron Opportunity Fund made the following comment about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in its Q1 2023 investor letter:
“Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biotechnology company specializing in RNA interference (RNAi) medications to treat a variety of diseases, detracted from performance. The company has lacked major wins in recent years, while also tallying some losses. Management’s late-stage drug licensing efforts to drive upfront and running royalties to bolster its balance sheet and ensure a longer cash runway have also pressured shares. Reinvigorating the company’s strategic story remains a key consideration for Arrowhead going forward. Last year, we reduced our portfolio weighting in Arrowhead but decided to maintain a foothold position. We believe Arrowhead’s efforts to target RNAi to the lungs will open a new therapeutic area of exploration. In our view, this initiative may lead to RNAi economies of scale, allow for an expansion of pipeline and collaboration opportunities, and generate a long runway for growth.”
2. Structure Therapeutics Inc. (NASDAQ:GPCR)
Average Upside Potential as of November 21: 185.26%
Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative oral treatments for chronic metabolic and pulmonary conditions with significant unmet medical needs. Its lead product candidate, GPCR-01, is an oral therapy aimed at treating obesity and related metabolic disorders.
The company recently announced its third-quarter 2024 financial results and corporate updates. It reported a strong financial position as of September 30, with $915.3 million in cash, cash equivalents, and short-term investments. This substantial funding is projected to sustain operations and key clinical milestones, including all GSBR-1290 studies necessary for Phase 3 readiness, until at least 2027.
It announced positive developments for GSBR-1290. This oral small molecule targets the GLP-1 receptor and holds promise as a treatment for obesity. The company initiated a comprehensive development program for GSBR-1290, which includes two Phase 2 clinical trials: ACCESS and ACCESS II. These studies aim to determine optimal dosing strategies and evaluate the drug’s effectiveness in adults with obesity or overweight and weight-related health problems. The first patients have already been enrolled in the ACCESS trial, with the expectation of including higher dosage groups in ACCESS II by year-end. Topline data from both studies is anticipated in late 2025.
While Structure Therapeutics Inc. (NASDAQ:GPCR) has other programs targeting obesity and related conditions, the focus is clearly on GSBR-1290’s progress. This suggests it’s the company’s most promising candidate at this stage. Overall, this progress reveals that it’s well-positioned for success in the industry.
Baron Health Care Fund stated the following regarding Structure Therapeutics Inc. (NASDAQ:GPCR) in its fourth quarter 2023 investor letter:
“Structure Therapeutics Inc. (NASDAQ:GPCR) is a biotechnology company dedicated to making oral small molecule medicines to target the obesity and diabetes market. Recent share weakness has been due to two large pharmaceutical acquisitions in the space: Roche’s purchase of Carmot and AstraZeneca’s in-licensing of Eccogene’s GLP-1 asset. These developments were followed by updates from Structure that implied it had a promising asset, but it might be inferior to Eli Lilly’s first-in-class product. Shares fell as analysts reduced the probability of success surrounding potential peak sales. We think it is too early to reach a final conclusion on the company’s oral small molecule GLP-1, as these data sets are limited in total sample size, and there are compelling arguments for both sides. Given how quickly this space changes and our smaller position sizing due to the aforementioned dynamics, we are monitoring our position and making decisions based on our evolving analysis.
We initiated a small position in Structure Therapeutics Inc., a clinical-stage biotechnology company. Structure is developing an oral small molecule GLP-1 with once daily dosing. We think the GLP-1 class of obesity/diabetes drugs has the potential to be the largest drug class ever and that parts of the market will be particularly well suited to oral medications. Some people find oral medications more convenient than injectables, and oral small molecule drugs are cheaper and easier to manufacture than injectables, which could allow for lower pricing and greater access, particularly in international markets. Structure’s drug is still in its early phase of development, but there is reason to think that it could be successful. The drug was designed through the company’s structure-based drug discovery platform and was designed to selectively activate the G-protein signaling pathway, which should lead to a better efficacy/safety profile. In late September, Structure announced promising results from a Phase 1 multiple ascending dose study in non-diabetic overweight/obese individuals. Although there were only a few patients in the study, the drug impressively demonstrated reductions in mean body weight of up to 4.9% placebo-adjusted after 28 days, which would suggest a best-in-class profile. Then, in December, Structure announced results from its Phase 2a study, including a diabetic cohort and a non-diabetic overweight/obese cohort. The interim data from the obesity cohort continued to look competitive with 4.7% placebo-adjusted weight loss after 56 days. The diabetes data was somewhat underwhelming, with a 1.0% placebo-adjusted HbA1c reduction and 3.3% to 3.5% placebo-adjusted weight loss over 84 days (in comparison, Lilly’s orforglipron showed a 1.5% to 1.7% HbA1c reduction and 4.1% to 6.3% placebo-adjusted weight loss in a similar study). Structure is planning to study additional doses and titration regimens to optimize the drug’s profile in diabetes. Overall, we would characterize the early data as supportive of an active GLP-1 drug that has the potential to be among the leaders in the category. At this point we have a small position in the stock while we await more data to evaluate the competitiveness of Structure’s drug.”
1. Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
Average Upside Potential as of November 21: 187.77%
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is a biotechnology company developing and commercializing cell therapies, primarily focusing on tumor-infiltrating lymphocyte (TIL) therapy for various solid tumors, including melanoma, renal cell carcinoma, non-small cell lung cancer, and gynecological cancers. Its lead product, Amtagvi, is a TIL therapy approved for metastatic melanoma.
Amtagvi’s FDA approval and successful commercial launch happened in the third quarter of 2024, resulting in a massive 12,385.07% year-over-year revenue improvement for the company, generating an amount of $58.56 million, surpassing expectations.
Amtagvi’s rapid adoption is evident in the increasing number of patient infusions, with 146 patients infused since its launch. This trajectory is expected to continue, with the company targeting a total of 70 authorized treatment centers (ATCs) by year-end. Favorable medical coverage policies and reimbursement are further facilitating broad access to Amtagvi, with ~75% of patients covered by private payers.
The company is well-positioned to capitalize on the significant commercial opportunity for Amtagvi. The US market alone represents a potential $1 billion peak opportunity, and the global market offers multi-billion dollar potential.
Artisan Small Cap Fund stated the following regarding Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in its Q2 2024 investor letter:
“Among our top detractors for the quarter were Lattice Semiconductor and Iovance Biotherapeutics, Inc. (NASDAQ:IOVA). Iovance Biotherapeutics is a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor-infiltrating lymphocyte (TIL) cell therapies for cancer patients. The stock rallied significantly in Q1 after announcing that the FDA approved AMTAGVI™ (lifileucel) for advanced melanoma. Now that the scientific risk is behind the company, investor focus has shifted to the company’s commercial execution, and shares experienced weakness after the company reported earnings results. It announced the enrollment of more than 100 patients for therapy; however, this was not enough to alleviate investor concerns about patient attrition. In our view, there is no issue with the efficacy of its life-saving treatment. Headwinds have been caused by challenges in ramping production, which is understandable in the early days. We view these concerns as overblown and remain invested.”
While we acknowledge the growth potential of Iovance Biotherapeutics Inc. (NASDAQ:IOVA), our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than IOVA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
